Should You Continue to Hold RMD Stock in Your Portfolio?
Resmed sees strong mask sales, strategic acquisitions and international expansion despite macro and competitive challenges.
IDEXX Laboratories Vs ResMed: Which Stock Could Rally?
IDEXX Laboratories' (IDXX) recent jump has investors questioning whether it's still the best bet—or if a stronger opportunity exists elsewhere. A closer look at its key competitor suggests there may be a clearer winner.
ResMed: Safe Bet For A Recession Environment
ResMed is rated a buy due to strong fundamentals, expanding margins, robust cash flow, and resilience in recessionary environments. RMD's steady topline growth, high profitability, low debt, and significant cash reserves position it favorably for investors who want to protect their portfolio for a recession. RMD's operational efficiency and cash balance support continued dividend growth and potential buybacks.
Resmed Stock Up on Q1 Earnings & Revenue Beat, Margins Expand
RMD's Q1 earnings and revenues top estimates as solid device and mask sales lift margins and boost investor confidence.
ResMed Inc. (RMD) Q1 2026 Earnings Call Transcript
ResMed Inc. ( RMD ) Q1 2026 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Sallilyn Schwartz - Chief Investor Relations Officer Michael Farrell - CEO & Chairman Brett Sandercock - Chief Financial Officer Conference Call Participants Davinthra Thillainathan - Goldman Sachs Group, Inc., Research Division Laura Sutcliffe - Citigroup Inc. Exchange Research Saul Hadassin - Barrenjoey Markets Pty Limited, Research Division Lyanne Harrison - BofA Securities, Research Division Steven Wheen - Jarden Limited, Research Division David Bailey - Morgan Stanley, Research Division Brett Fishbin - KeyBanc Capital Markets Inc., Research Division Joseph Conway - Needham & Company, LLC, Research Division Dan Hurren - MST Financial Services Pty Limited, Research Division Presentation Operator Hello, and welcome to the Q1 Fiscal Year 2026 ResMed Earnings Conference Call. My name is Kevin.
Compared to Estimates, ResMed (RMD) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ResMed (RMD) Q1 Earnings and Revenues Beat Estimates
ResMed (RMD) came out with quarterly earnings of $2.55 per share, beating the Zacks Consensus Estimate of $2.49 per share. This compares to earnings of $2.2 per share a year ago.
Seeking Clues to ResMed (RMD) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for ResMed (RMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb
RMD tops Q4 earnings and revenue estimates with double-digit growth, rising margins and strong global device demand.
